SPI-1005 (ebselen) open-label Phase 3 safety study in Meniere's disease
Trial details
- Registry identifier: NCT06859788 on ClinicalTrials.gov
- Phase: Phase 3
- Status: Active, not recruiting
- Sponsor: Sound Pharmaceuticals
- Planned enrollment: 200
- Estimated completion: Dec 2026
- Country: USA
Why this trial matters
The most advanced drug program with tinnitus-relevant outcomes; enrollment completed July 2026. Tinnitus is a secondary, patient-reported outcome.
Related treatment evidence
Trial statuses are verified against the ClinicalTrials.gov registry by our weekly automated check. A tracked trial is research in progress — inclusion is not a treatment recommendation, and only the study team can determine eligibility.